Log In
Print this Print this

Biosimilar adalimumab (GP2017)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar version of adalimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe plaque-type psoriasis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today